Browse the corpus

Index Note: Page numbers followed by f and t denote figure and table, respectively. Antiphospholipid antibody syndrome, 52 Test questions are indicated by Q. Antireflux surgery, for GERD, 5 Antispasmotics, for IBS-D, 39 A Antiviral therapy Abscesses, hepatic, 68, Q5 for HBV, 55-57, Q47 Acalculous cholecystitis, 72-73, 73f during pregnancy, 70 Acarbose, for dumping syndrome, 19 Aortoenteric fistulae, 75t, 78, 79t, 80-81 ACE inhibitors, 27t, 65, Q3 APC mutations, 48 Acetaminophen, liver injury induced by, 59 Aphthous ulcers, in Crohn disease, 33 Achalasia, 1, 6-7, Q41 Apixaban, withholding during LGIB, Q64 Acute cholecystitis, 72, Q74 Arteriovenous malformations, LGIB and, 80 Acute fatty liver of pregnancy, 60t, 71 Ascites Acute liver failure, 60, 60t causes of, Q54 Acute mesenteric ischemia (AMI), 41, 41t, Q33 characteristics of, 65t Acute pancreatitis, 19-21, Q12, Q16, Q96 evaluation of, Q54 Acute Physiologic Assessment and Chronic Health Evaluation liver disease and, 64-65 (APACHE) II score, 20 management in cirrhosis, Q3 Acute viral hepatitis, liver chemistry in, 53t neutrophil count in, 65 Adalimumab, 34t, 35 renal dysfunction and, Q38 Adefovir, for HBV infection, 55 SBP and, 65 Adenocarcinoma, pancreatic, 24 Aspartate aminotransferase (AST) elevation, 52 Adenomatous polyposis coli (APC) gene, 45 Aspirin, 12, 15, 46, 77-78, Q94 Adenomatous polyposis syndromes, 48-51 Asterixis, in HE, 66t Alanine aminotransferase (ALT) levels, 20, 52, 53t, 54t Asthma, GERD and, 5 Albumin, serum levels, 52 Atezolumab, for HCC, 69 Albumin therapy, 65, 66, Q39 Atrophic gastritis, 14-15, 18 Alcohol use, chronic pancreatitis and, 22t Attenuated FAP, features of, 49t Alcoholic hepatitis, 53t, 58-59, Q7 Autoimmune atrophic gastritis, 14-15 Alcohol-induced liver disease, 58-59 Autoimmune hepatitis, 53t, 58, 70, Q18 Alkaline phosphatase (ALP) levels, 52, 53t Autoimmune pancreatitis (AIP), 23-24, 23f, Q1 Alosetron, 39 Azathioprine o,-Antitrypsin deficiency, 53t, 61 for autoimmune hepatitis, 58 Ambulatory pH monitoring, in GERD, 4 for autoimmune pancreatitis, 24 Amebic liver abscesses, 68 for Crohn disease, 34t 5-Aminosalicylates (5-ASAs), 34, 34t, Q20, Q48 during pregnancy, 70 Amoxicillin, for H. pylori infection, 13t, 14t for relapsed ulcerative colitis, Q61 Amoxicillin-clavulanate, liver injury induced by, 59 for ulcerative colitis, 34, 34t Ampulla of Vater, adenocarcinoma of, 26 Ampullary adenocarcinoma, 26 B Amsterdam II criteria, 48, 50t Balsalazide, for IBD, 34 Amyloidosis, small-bowel bleeding and, 80-81 Barium esophagography, 1, 3f, 7f Anal cancer, 44, 44f Barium swallow, 1 Anal fissures, 43-44, 43f, Q46 Barrett esophagus, 3-4, 8-9, 9t, QI7 Analgesics, for patients with liver disease, 67, Q82 Barrett mucosa, 9f Andexanet alfa, pre-endoscopic, 77 B-Blocker therapy, postendoscopy, 78 Androgen treatment, hepatic adenomas and, 68 Bethesda criteria, 48, 50t Anemia, treatment of, 82 Bevacizumab, for HCC, 69 Angiectasia, LGIB and, 80 Bilateral salpingo-oophorectomy, prophylactic, 48 Angiodysplasia, 79t, 80-81, 81f, 81t Bile acid sequestrants, for IBS-D, 39 Angiographic embolization, 80 Bile duct disorders, 62f, 71-75 Angiotensin receptor blockers, diarrhea caused by, 27t Biliary cholangitis, HCC screening in, 69t Anorectal disorders, 42-45 Biliary colic, 72 Antacids, 4, 27t Bilirubin, forms of, 52 Anthracycline derivatives, in HBV prophylaxis, 56 Biofeedback, for constipation, 38t Anthraquinones, for constipation, 38t Bisacodyl, for constipation, 37, 38t Antibiotics Bismuth, 13t, 14t, 28, Q87 diarrhea caused by, 27t Bisphosphonates, for osteoporosis, 12, 67 liver injury induced by, 59 Blue rubber bleb nevus syndrome, 80-81 Anticoagulation therapy BMPRIA mutations, 51 LGIB management and, Q64, Q94 Botulinum toxin, LES injection of, 7 for mesenteric ischemia, 41 Bowel infarction, 41 for portal vein thrombosis, 71 BRCA2 mutations, 24 postendoscopic, 78 Budd-Chiari syndrome, 63, 71, Q10 reinitiation after UGIB treatment, Q77 Budesonide, 28, 34t reversal of, 76 Bulking agents, for constipation, 37 Anti-deamidated gliadin peptide IgG antibody test, 29, Q9 Antidepressants, for gastroparesis, 16 € Antiemetics, for gastroparesis, 16 Calcium channel blockers, for achalasia, 7 Antiepileptics, liver injury induced by, 59 Calcium polycarbophil, for constipation, 38t Antifungal agents, liver injury induced by, 60 Calcium supplementation, 62, 67 Antimitochondrial antibody (AMA) test, 53, 62, Q2 Cameron erosion, features of, 75t

Note: Page numbers followed by f and t denote figure and table, respectively. Antiphospholipid antibody syndrome, 52 Test questions are indicated by Q. Antireflux surgery, for GERD, 5 Antispasmotics, for IBS-D, 39 A Antiviral therapy Abscesses, hepatic, 68, Q5 for HBV, 55-57, Q47 Acalculous cholecystitis, 72-73, 73f during pregnancy, 70 Acarbose, for dumping syndrome, 19 Aortoenteric fistulae, 75t, 78, 79t, 80-81 ACE inhibitors, 27t, 65, Q3 APC mutations, 48 Acetaminophen, liver injury induced by, 59 Aphthous ulcers, in Crohn disease, 33 Achalasia, 1, 6-7, Q41 Apixaban, withholding during LGIB, Q64 Acute cholecystitis, 72, Q74 Arteriovenous malformations, LGIB and, 80 Acute fatty liver of pregnancy, 60t, 71 Ascites Acute liver failure, 60, 60t causes of, Q54 Acute mesenteric ischemia (AMI), 41, 41t, Q33 characteristics of, 65t Acute pancreatitis, 19-21, Q12, Q16, Q96 evaluation of, Q54 Acute Physiologic Assessment and Chronic Health Evaluation liver disease and, 64-65 (APACHE) II score, 20 management in cirrhosis, Q3 Acute viral hepatitis, liver chemistry in, 53t neutrophil count in, 65 Adalimumab, 34t, 35 renal dysfunction and, Q38 Adefovir, for HBV infection, 55 SBP and, 65 Adenocarcinoma, pancreatic, 24 Aspartate aminotransferase (AST) elevation, 52 Adenomatous polyposis coli (APC) gene, 45 Aspirin, 12, 15, 46, 77-78, Q94 Adenomatous polyposis syndromes, 48-51 Asterixis, in HE, 66t Alanine aminotransferase (ALT) levels, 20, 52, 53t, 54t Asthma, GERD and, 5 Albumin, serum levels, 52 Atezolumab, for HCC, 69 Albumin therapy, 65, 66, Q39 Atrophic gastritis, 14-15, 18 Alcohol use, chronic pancreatitis and, 22t Attenuated FAP, features of, 49t Alcoholic hepatitis, 53t, 58-59, Q7 Autoimmune atrophic gastritis, 14-15 Alcohol-induced liver disease, 58-59 Autoimmune hepatitis, 53t, 58, 70, Q18 Alkaline phosphatase (ALP) levels, 52, 53t Autoimmune pancreatitis (AIP), 23-24, 23f, Q1 Alosetron, 39 Azathioprine o,-Antitrypsin deficiency, 53t, 61 for autoimmune hepatitis, 58 Ambulatory pH monitoring, in GERD, 4 for autoimmune pancreatitis, 24 Amebic liver abscesses, 68 for Crohn disease, 34t 5-Aminosalicylates (5-ASAs), 34, 34t, Q20, Q48 during pregnancy, 70 Amoxicillin, for H. pylori infection, 13t, 14t for relapsed ulcerative colitis, Q61 Amoxicillin-clavulanate, liver injury induced by, 59 for ulcerative colitis, 34, 34t Ampulla of Vater, adenocarcinoma of, 26 Ampullary adenocarcinoma, 26 B Amsterdam II criteria, 48, 50t Balsalazide, for IBD, 34 Amyloidosis, small-bowel bleeding and, 80-81 Barium esophagography, 1, 3f, 7f Anal cancer, 44, 44f Barium swallow, 1 Anal fissures, 43-44, 43f, Q46 Barrett esophagus, 3-4, 8-9, 9t, QI7 Analgesics, for patients with liver disease, 67, Q82 Barrett mucosa, 9f Andexanet alfa, pre-endoscopic, 77 B-Blocker therapy, postendoscopy, 78 Androgen treatment, hepatic adenomas and, 68 Bethesda criteria, 48, 50t Anemia, treatment of, 82 Bevacizumab, for HCC, 69 Angiectasia, LGIB and, 80 Bilateral salpingo-oophorectomy, prophylactic, 48 Angiodysplasia, 79t, 80-81, 81f, 81t Bile acid sequestrants, for IBS-D, 39 Angiographic embolization, 80 Bile duct disorders, 62f, 71-75 Angiotensin receptor blockers, diarrhea caused by, 27t Biliary cholangitis, HCC screening in, 69t Anorectal disorders, 42-45 Biliary colic, 72 Antacids, 4, 27t Bilirubin, forms of, 52 Anthracycline derivatives, in HBV prophylaxis, 56 Biofeedback, for constipation, 38t Anthraquinones, for constipation, 38t Bisacodyl, for constipation, 37, 38t Antibiotics Bismuth, 13t, 14t, 28, Q87 diarrhea caused by, 27t Bisphosphonates, for osteoporosis, 12, 67 liver injury induced by, 59 Blue rubber bleb nevus syndrome, 80-81 Anticoagulation therapy BMPRIA mutations, 51 LGIB management and, Q64, Q94 Botulinum toxin, LES injection of, 7 for mesenteric ischemia, 41 Bowel infarction, 41 for portal vein thrombosis, 71 BRCA2 mutations, 24 postendoscopic, 78 Budd-Chiari syndrome, 63, 71, Q10 reinitiation after UGIB treatment, Q77 Budesonide, 28, 34t reversal of, 76 Bulking agents, for constipation, 37 Anti-deamidated gliadin peptide IgG antibody test, 29, Q9 Antidepressants, for gastroparesis, 16 € Antiemetics, for gastroparesis, 16 Calcium channel blockers, for achalasia, 7 Antiepileptics, liver injury induced by, 59 Calcium polycarbophil, for constipation, 38t Antifungal agents, liver injury induced by, 60 Calcium supplementation, 62, 67 Antimitochondrial antibody (AMA) test, 53, 62, Q2 Cameron erosion, features of, 75t 157

Index Campylobacter spp., 26 Condylomata, anal cancer and, 44 Cancer, risks in IBD, 36. See also Specific cancers Congestive hepatopathy, liver chemistry in, 53t Candida esophagitis, 6, 6f, Q89 Conjugated hyperbilirubinemia, 52 Carbamazepine, diarrhea caused by, 27t Constipation, 36-38 Carbohydrate malabsorption, 31 causes of, 37t Cartolizumab, for Crohn disease, 34t chronic, Q14 Carvedilol, postendoscopy for UGIB, 78 evaluation of, 37 Cascara, for constipation, 38t indications for colonoscopy in, Q14 Cefotaxime, for SBP, Q39 management of, 37-38 Ceftriaxone, pre-endoscopic, 76-77 narcotic bowel syndrome and, Q31 Celecoxib, for NSAID-induced PUD prevention, Q53 Corkscrew esophagus, 8f Celiac disease, 29-30 Cough, GERD and, 5 IgGa deficiency and. Q9 Cowden syndrome, 51 liver chemistry in, 53t COX-2 inhibitors, 15-16 management of, Q95 Crohn disease, 31-36, 32t, 46, Q66 recurrent, Q45 Cryptosporidia, diarrhea caused by, 26 Centrally mediated abdominal pain syndrome (CAPS), 39-40 Cryptosporidium spp., esophagitis and, 6 Certolizumab, for Crohn disease, 35 Cutaneous telangiectasia, 81 Cervical cancer screening, Q28 Cyclooxygenase-2 inhibitors, cancer risk and, 46 Cervical dysplasia, risks in IBD patients, 36 Cyclosporine, for ulcerative colitis, 34t, 35 Charcot triad, 73 Cystic duct obstruction, 72 Chemotherapy, diarrhea caused by, 27t Cysts Chest pain, dysphagia and, 2-3 hepatic, 68 Child-Turcotte-Pugh (CTP) scores, 63, 63t pancreatic, 24-25, 25f Cholangiocarcinoma, 62, 74-75 Cytokine cascades, 21 Cholangitis, 73-74, Q83 Cytomegalovirus (CMV), 58t Cholecystectomy for gallstone pancreatitis, Q96 D indications for, 71, 72, Q74, Q84 Decompensated cirrhosis, 71, Q3 Cholecystitis, acute, 72, Q74 Depression, in IBD patients, 36 Choledocholithiasis, 73f Dermatitis herpetiformis, 29-30, 30f, Q92 Cholera, diarrhea caused by, 26 Diabetes mellitus, 16-17, 24, 60-61, Q35 Cholestatic liver disease, 62-63 Diarrhea Cholesterol stones, 71 acute, 26 Chronic autoimmune hepatitis, 53t causes of, 26, 27t Chronic constipation, colonoscopy in, Q14 chronic, 26-28 Chronic diarrhea, types, 27t fructose malabsorption and, Q40 Chronic liver hepatitis, liver chemistry in, 53t lactase deficiency and, Q37 Chronic mesenteric ischemia (CMI), 41-42, 41t, Q63 loperamide for, Q86 Chronic pancreatitis, 22-23, 22t, Q93 medications causing, 27t, Q34, Q59 Chylous ascites, features of, 65t osmotic, Q40 Ciprofloxacin, 21, 35, 40 stool testing for Giardia spp., Q22 Cirrhosis, 52 Dicyclomine, for IBS-D, 39 alcohol-induced, 58-59 Diet. See also Lifestyle changes ascites in, 64-65, 65t, Q3 celiac disease management and, Q95 chronic HBV infection and, 55, 55t for diverticulitis, 40 evaluation of dyspnea in, Q80 dumping syndrome management, Q42 HCC and, 69, Q30 for gastroparesis, 16-17 imaging gastric varices in, Q24 for GERD, 4 pain management in, Q82 gluten-free, 29-30 renal dysfunction in, Q38 for IBS, 39 Clarithromycin, for H. pylori infection, 13t, 14t for lactase deficiency, Q37 CLDN2 gene, 22, 22t recurrent celiac disease, Q45 Clostridioides difficile, 26 Dieulafoy lesion, 75t, 79-81, 79t Colchicine, diarrhea caused by, 27t Diffuse esophageal spasm, 7, 8f Colectomy, for colon cancer, Q25 Diphenylmethanes, for constipation, 38t Colesevelam, for IBS-D, 39 Diuretic therapy, for ascites, 65 Collagenous colitis, 28, 28f Diverticulitis, 40, Q6 Colon, serrated lesion of, 45f Diverticulosis, 40, 79t Colon cancer, colectomy for, Q25 Docusate, for constipation, 37, 38t Colonic angiodysplasia, LGIB and, 79 Drug-induced liver injury, 59-60, Q55 Colonic ischemia, 42, 42f, 79t, Q19 Dumping syndrome, 18-19, Q42 Colonoscopy Duodenal ulcers, 76f, 77f cancer screening with, 47 Duodenum, disorders of, 10-19 diagnostic, 28 Dyspepsia, 10-11, 10t, 11t indications for, Q14 Dysphagia, globus sensation and, 2 for LGIB, 80, Q65 Dysphagia, 1, 2t surveillance, Q62 Dyspnea, in cirrhosis patient, Q80 Colorectal cancer, hereditary syndromes, 47-52, 49t Dyssynergic defecation, 37 Colorectal neoplasia, 45-52 chemoprevention, 46 E epidemiology of. 45 Echocardiography, indications for, Q80 Lynch syndrome and, 47-48, 49t, 50t Elastography, 52 pathogenesis of, 45 Eluxadoline, 39 polyps, 47t Endometrial cancer, Q79 risk factors for, 45-46, 46t Endoscopic retrograde cholangiopancreatography (ERCP), 20, 62, screening for, 46-47, 46t 73, 73f, Q83 staging of, 47 Endoscopy capsule, 81f surveillance of, 47, 48t Endothelin receptor analogs, 67 Colorectal polyps, classification of, 47t Entamoeba histolytica diarrhea, 26 Common bile duct stones, 73-74 Entecavir, for HBV infection, 55 Compensated cirrhosis, 64-65, 64t, Q30 Enteral feeding, in acute pancreatitis, 20

Campylobacter spp., 26 Condylomata, anal cancer and, 44 Cancer, risks in IBD, 36. See also Specific cancers Congestive hepatopathy, liver chemistry in, 53t Candida esophagitis, 6, 6f, Q89 Conjugated hyperbilirubinemia, 52 Carbamazepine, diarrhea caused by, 27t Constipation, 36-38 Carbohydrate malabsorption, 31 causes of, 37t Cartolizumab, for Crohn disease, 34t chronic, Q14 Carvedilol, postendoscopy for UGIB, 78 evaluation of, 37 Cascara, for constipation, 38t indications for colonoscopy in, Q14 Cefotaxime, for SBP, Q39 management of, 37-38 Ceftriaxone, pre-endoscopic, 76-77 narcotic bowel syndrome and, Q31 Celecoxib, for NSAID-induced PUD prevention, Q53 Corkscrew esophagus, 8f Celiac disease, 29-30 Cough, GERD and, 5 IgGa deficiency and. Q9 Cowden syndrome, 51 liver chemistry in, 53t COX-2 inhibitors, 15-16 management of, Q95 Crohn disease, 31-36, 32t, 46, Q66 recurrent, Q45 Cryptosporidia, diarrhea caused by, 26 Centrally mediated abdominal pain syndrome (CAPS), 39-40 Cryptosporidium spp., esophagitis and, 6 Certolizumab, for Crohn disease, 35 Cutaneous telangiectasia, 81 Cervical cancer screening, Q28 Cyclooxygenase-2 inhibitors, cancer risk and, 46 Cervical dysplasia, risks in IBD patients, 36 Cyclosporine, for ulcerative colitis, 34t, 35 Charcot triad, 73 Cystic duct obstruction, 72 Chemotherapy, diarrhea caused by, 27t Cysts Chest pain, dysphagia and, 2-3 hepatic, 68 Child-Turcotte-Pugh (CTP) scores, 63, 63t pancreatic, 24-25, 25f Cholangiocarcinoma, 62, 74-75 Cytokine cascades, 21 Cholangitis, 73-74, Q83 Cytomegalovirus (CMV), 58t Cholecystectomy for gallstone pancreatitis, Q96 D indications for, 71, 72, Q74, Q84 Decompensated cirrhosis, 71, Q3 Cholecystitis, acute, 72, Q74 Depression, in IBD patients, 36 Choledocholithiasis, 73f Dermatitis herpetiformis, 29-30, 30f, Q92 Cholera, diarrhea caused by, 26 Diabetes mellitus, 16-17, 24, 60-61, Q35 Cholestatic liver disease, 62-63 Diarrhea Cholesterol stones, 71 acute, 26 Chronic autoimmune hepatitis, 53t causes of, 26, 27t Chronic constipation, colonoscopy in, Q14 chronic, 26-28 Chronic diarrhea, types, 27t fructose malabsorption and, Q40 Chronic liver hepatitis, liver chemistry in, 53t lactase deficiency and, Q37 Chronic mesenteric ischemia (CMI), 41-42, 41t, Q63 loperamide for, Q86 Chronic pancreatitis, 22-23, 22t, Q93 medications causing, 27t, Q34, Q59 Chylous ascites, features of, 65t osmotic, Q40 Ciprofloxacin, 21, 35, 40 stool testing for Giardia spp., Q22 Cirrhosis, 52 Dicyclomine, for IBS-D, 39 alcohol-induced, 58-59 Diet. See also Lifestyle changes ascites in, 64-65, 65t, Q3 celiac disease management and, Q95 chronic HBV infection and, 55, 55t for diverticulitis, 40 evaluation of dyspnea in, Q80 dumping syndrome management, Q42 HCC and, 69, Q30 for gastroparesis, 16-17 imaging gastric varices in, Q24 for GERD, 4 pain management in, Q82 gluten-free, 29-30 renal dysfunction in, Q38 for IBS, 39 Clarithromycin, for H. pylori infection, 13t, 14t for lactase deficiency, Q37 CLDN2 gene, 22, 22t recurrent celiac disease, Q45 Clostridioides difficile, 26 Dieulafoy lesion, 75t, 79-81, 79t Colchicine, diarrhea caused by, 27t Diffuse esophageal spasm, 7, 8f Colectomy, for colon cancer, Q25 Diphenylmethanes, for constipation, 38t Colesevelam, for IBS-D, 39 Diuretic therapy, for ascites, 65 Collagenous colitis, 28, 28f Diverticulitis, 40, Q6 Colon, serrated lesion of, 45f Diverticulosis, 40, 79t Colon cancer, colectomy for, Q25 Docusate, for constipation, 37, 38t Colonic angiodysplasia, LGIB and, 79 Drug-induced liver injury, 59-60, Q55 Colonic ischemia, 42, 42f, 79t, Q19 Dumping syndrome, 18-19, Q42 Colonoscopy Duodenal ulcers, 76f, 77f cancer screening with, 47 Duodenum, disorders of, 10-19 diagnostic, 28 Dyspepsia, 10-11, 10t, 11t indications for, Q14 Dysphagia, globus sensation and, 2 for LGIB, 80, Q65 Dysphagia, 1, 2t surveillance, Q62 Dyspnea, in cirrhosis patient, Q80 Colorectal cancer, hereditary syndromes, 47-52, 49t Dyssynergic defecation, 37 Colorectal neoplasia, 45-52 chemoprevention, 46 E epidemiology of. 45 Echocardiography, indications for, Q80 Lynch syndrome and, 47-48, 49t, 50t Elastography, 52 pathogenesis of, 45 Eluxadoline, 39 polyps, 47t Endometrial cancer, Q79 risk factors for, 45-46, 46t Endoscopic retrograde cholangiopancreatography (ERCP), 20, 62, screening for, 46-47, 46t 73, 73f, Q83 staging of, 47 Endoscopy capsule, 81f surveillance of, 47, 48t Endothelin receptor analogs, 67 Colorectal polyps, classification of, 47t Entamoeba histolytica diarrhea, 26 Common bile duct stones, 73-74 Entecavir, for HBV infection, 55 Compensated cirrhosis, 64-65, 64t, Q30 Enteral feeding, in acute pancreatitis, 20 158

Index Environmental metaplastic atrophic gastritis, 14 for IBD, 33f Eosinophilic esophagitis (EoE), 5-6, 6f, Q29 for ulcerative colitis, 34t Eosinophilic gastritis, 15 Glucose breath test, Q67 Epigastric pain syndrome, 11t Glucose-6-phosphate dehydrogenase, 30, Q92 Epiglottis, function of, 1 Gluten, 29-30, Q45 Episcleritis, in IBD, 32 Glycogen storage diseases, 68 Erosive gastropathy, 14 Golimumab, for ulcerative colitis, 34t, 35 Erythema nodosum in IBD, 32, 32f Granulomas, hepatic, 69 Erythromycin, 16, 76 Gynecomastia, 59 Escherichia coli diarrhea, 26 Esomeprazole, for high risk UGIB, Q88 H Esophageal adenocarcinoma, 3-4 H, blockers, 4, 15-16 Esophageal carcinoma, 9 Hamartomas, GI, 51-52 Esophageal dysphagia, 1, 2t, Q50 Hamartomatous polyposis syndromes, 51-52 Esophageal manometry, 1, 4 Hamartomatous polyps, 47t Esophageal varices, 63-64, 64f, 64t, 78f HBV immune globulin, during pregnancy, 70 Esophagitis, 5-6, 6f, Q89 Heart failure, ascites in, 65t Esophagus Heartburn, 4, 10, Q49 “bird's beak” narrowing of, 7, 7f Helicobacter pylori “corkscrew,” 8f diagnosis, 13 disorders of, 1-10 eradication testing, 14 motility disorders, 6-8 peptic ulcer disease and, 12 obstruction of, 1 stool antigen testing for, Q70 spastic disorders of, 7 testing for, 11, 11f, 13 strictures of, 1 treatment of infection, 13-14, 13t, 14t, Q87 UGIB and, 75 F HELLP (hemolysis, elevated liver enzymes, low platelet) Familial adenomatous polyposis (FAP) syndrome, 48-50, syndrome, 70-71, Q36 49t, 50f, Q25 Hemangioma, small-bowel bleeding and, 81t Familial atypical multiple-mole melanoma, 24 Hematemesis, 4, 12 Familial pancreatic cancer, 24 Hematochezia, 12, 41, 42 Fecal elastase, 28 Hemochromatosis, liver chemistry in, 53t Fecal fat, 28 Hemorrhoidectomy, 43 Fecal incontinence, 44 Hemorrhoids, 43, 43f Fiber supplements, 37, 39 Henoch-Schénlein purpura, 80-81 Fibrosis, alcohol-induced, 58-59 Hepatic abscesses, 68, QS Fistulae, in Crohn disease, 31 Hepatic adenomas, 68, Q43 Fluconazole, for Candida esophagitis, Q89 Hepatic cysts, 68-70 Fluid resuscitation, for pancreatitis, 20 Hepatic encephalopathy (HE), 60, 66, 66t, Q75 Fluoroquinolone, for SBP, 65 Hepatic granulomas, 69 Focal nodular hyperplasia (FNH), 68 Hepatic hemangiomas, 68 FODMAP diet, 28, 28t, 39 Hepatic ischemia, liver chemistry in, 53t Fructose malabsorption, 27, 27t, 29, 31, Q40 Hepatic sarcoidosis, Q51 Functional dyspepsia, 10, 11f, Q85 Hepatitis A virus (HAV), 53, QU Functional gallbladder disorder, 73, 73f Hepatitis B surface antigen (HBsAg), 54 Fundic gland polyps, 48, Q72 Hepatitis B virus (HBV), 54-56, 54t, 55f, 55t, 70, Q4, Q47 Hepatitis C virus (HCV), 56-57, 56f, 56t, 70, Q58 G Hepatitis D virus (HDV), 57 Gabapentin, for chronic pancreatitis, 23 Hepatitis E virus (HEV), 57 Gallbladder, 71-75, 72f, 74t Hepatobiliary disorders, liver chemistry in, 53t Gallbladder cancer, 74 Hepatocellular carcinoma (HCC), 69 Gallbladder disorders, 71-75 chronic HBV infection and, 55, 55t Gallbladder polyps, 74, 74f, Q84 compensated cirrhosis and, Q30 Gallstone pancreatitis, 20, Q96 screening for, 69t Gallstones, asymptomatic, 71-72, 72f, Q78 surgical management of, Q26 Gastric adenocarcinoma, 18 surveillance in, 69t Gastric antral vascular ectasias, 64f, 75t Hepatolenticular degeneration, 61 Gastric emptying, assessment of, 16-17, 17t Hepatomegaly, 58 Gastric intestinal metaplasia, 14-15 Hepatopulmonary syndrome (HPS), 66 Gastric polyps, 17 Hepatorenal syndrome (HRS), 66 Gastric scintigraphy, 16, 17t, Q90 Hereditary colorectal cancer syndromes, 47-52, 49t Gastric subepithelial lesions, 17-18 Hereditary hemochromatosis, 61, Q21 Gastric surgery, complications of, 18-19 Hereditary hemorrhagic telangiectasia, 81f, 81t Gastric ulcers, 77f, Q73 Hereditary pancreatitis, 24 Gastric varices, 64, Q24 Hernobilia, features of, 75t Gastrinomas, 25, 26 Hernosuccus pancreaticus, 75t Gastroesophageal reflux disease (GERD), 2-5, 3t, Herpes simplex virus, viral hepatitis and. 58t 4f, 10, Q17, Q81 Hiatal hernias, 1 Gastroesophageal varices, 75t HIV, anal cancer and, 44 Gastrointestinal bleeding, 75-82 HLA-DQ? gene, 29-30 Gastrointestinal neuroendocrine tumors, 17-18 HLA-DQ8 gene, 29-30 Gastrointestinal stromal tumors (GISTs), 17 Human papillomavirus, 44 Gastroparesis, 16-17, 16t, Q90 Hyperbilirubinemia, 20, 52 Giardia duodenalis diarrhea, 26 Hyperemesis gravidarum, 70 Giardia spp., stool testing for, Q22 Hyperplastic polyps, 47t, Q8 Gilbert syndrome, 52 Hypertonic motility disorders, 6-7 Glasgow-Blatchford bleeding score, 77 Hypertriglyceridemia, 20 Globus sensation, 2 Hypocalcemia, pancreatitis and, 21 Glucocorticoids Hypomotility disorder, Q49 for autoimmune pancreatitis, 24 Hypotonic motility disorders, 7-8 for Crohn disease, 34t, 35 Hypovolemia, colonic ischemia and, 42 for hepatic encephalopathy, 59 Hysterectomy, prophylactic, 48

Environmental metaplastic atrophic gastritis, 14 for IBD, 33f Eosinophilic esophagitis (EoE), 5-6, 6f, Q29 for ulcerative colitis, 34t Eosinophilic gastritis, 15 Glucose breath test, Q67 Epigastric pain syndrome, 11t Glucose-6-phosphate dehydrogenase, 30, Q92 Epiglottis, function of, 1 Gluten, 29-30, Q45 Episcleritis, in IBD, 32 Glycogen storage diseases, 68 Erosive gastropathy, 14 Golimumab, for ulcerative colitis, 34t, 35 Erythema nodosum in IBD, 32, 32f Granulomas, hepatic, 69 Erythromycin, 16, 76 Gynecomastia, 59 Escherichia coli diarrhea, 26 Esomeprazole, for high risk UGIB, Q88 H Esophageal adenocarcinoma, 3-4 H, blockers, 4, 15-16 Esophageal carcinoma, 9 Hamartomas, GI, 51-52 Esophageal dysphagia, 1, 2t, Q50 Hamartomatous polyposis syndromes, 51-52 Esophageal manometry, 1, 4 Hamartomatous polyps, 47t Esophageal varices, 63-64, 64f, 64t, 78f HBV immune globulin, during pregnancy, 70 Esophagitis, 5-6, 6f, Q89 Heart failure, ascites in, 65t Esophagus Heartburn, 4, 10, Q49 “bird's beak” narrowing of, 7, 7f Helicobacter pylori “corkscrew,” 8f diagnosis, 13 disorders of, 1-10 eradication testing, 14 motility disorders, 6-8 peptic ulcer disease and, 12 obstruction of, 1 stool antigen testing for, Q70 spastic disorders of, 7 testing for, 11, 11f, 13 strictures of, 1 treatment of infection, 13-14, 13t, 14t, Q87 UGIB and, 75 F HELLP (hemolysis, elevated liver enzymes, low platelet) Familial adenomatous polyposis (FAP) syndrome, 48-50, syndrome, 70-71, Q36 49t, 50f, Q25 Hemangioma, small-bowel bleeding and, 81t Familial atypical multiple-mole melanoma, 24 Hematemesis, 4, 12 Familial pancreatic cancer, 24 Hematochezia, 12, 41, 42 Fecal elastase, 28 Hemochromatosis, liver chemistry in, 53t Fecal fat, 28 Hemorrhoidectomy, 43 Fecal incontinence, 44 Hemorrhoids, 43, 43f Fiber supplements, 37, 39 Henoch-Schénlein purpura, 80-81 Fibrosis, alcohol-induced, 58-59 Hepatic abscesses, 68, QS Fistulae, in Crohn disease, 31 Hepatic adenomas, 68, Q43 Fluconazole, for Candida esophagitis, Q89 Hepatic cysts, 68-70 Fluid resuscitation, for pancreatitis, 20 Hepatic encephalopathy (HE), 60, 66, 66t, Q75 Fluoroquinolone, for SBP, 65 Hepatic granulomas, 69 Focal nodular hyperplasia (FNH), 68 Hepatic hemangiomas, 68 FODMAP diet, 28, 28t, 39 Hepatic ischemia, liver chemistry in, 53t Fructose malabsorption, 27, 27t, 29, 31, Q40 Hepatic sarcoidosis, Q51 Functional dyspepsia, 10, 11f, Q85 Hepatitis A virus (HAV), 53, QU Functional gallbladder disorder, 73, 73f Hepatitis B surface antigen (HBsAg), 54 Fundic gland polyps, 48, Q72 Hepatitis B virus (HBV), 54-56, 54t, 55f, 55t, 70, Q4, Q47 Hepatitis C virus (HCV), 56-57, 56f, 56t, 70, Q58 G Hepatitis D virus (HDV), 57 Gabapentin, for chronic pancreatitis, 23 Hepatitis E virus (HEV), 57 Gallbladder, 71-75, 72f, 74t Hepatobiliary disorders, liver chemistry in, 53t Gallbladder cancer, 74 Hepatocellular carcinoma (HCC), 69 Gallbladder disorders, 71-75 chronic HBV infection and, 55, 55t Gallbladder polyps, 74, 74f, Q84 compensated cirrhosis and, Q30 Gallstone pancreatitis, 20, Q96 screening for, 69t Gallstones, asymptomatic, 71-72, 72f, Q78 surgical management of, Q26 Gastric adenocarcinoma, 18 surveillance in, 69t Gastric antral vascular ectasias, 64f, 75t Hepatolenticular degeneration, 61 Gastric emptying, assessment of, 16-17, 17t Hepatomegaly, 58 Gastric intestinal metaplasia, 14-15 Hepatopulmonary syndrome (HPS), 66 Gastric polyps, 17 Hepatorenal syndrome (HRS), 66 Gastric scintigraphy, 16, 17t, Q90 Hereditary colorectal cancer syndromes, 47-52, 49t Gastric subepithelial lesions, 17-18 Hereditary hemochromatosis, 61, Q21 Gastric surgery, complications of, 18-19 Hereditary hemorrhagic telangiectasia, 81f, 81t Gastric ulcers, 77f, Q73 Hereditary pancreatitis, 24 Gastric varices, 64, Q24 Hernobilia, features of, 75t Gastrinomas, 25, 26 Hernosuccus pancreaticus, 75t Gastroesophageal reflux disease (GERD), 2-5, 3t, Herpes simplex virus, viral hepatitis and. 58t 4f, 10, Q17, Q81 Hiatal hernias, 1 Gastroesophageal varices, 75t HIV, anal cancer and, 44 Gastrointestinal bleeding, 75-82 HLA-DQ? gene, 29-30 Gastrointestinal neuroendocrine tumors, 17-18 HLA-DQ8 gene, 29-30 Gastrointestinal stromal tumors (GISTs), 17 Human papillomavirus, 44 Gastroparesis, 16-17, 16t, Q90 Hyperbilirubinemia, 20, 52 Giardia duodenalis diarrhea, 26 Hyperemesis gravidarum, 70 Giardia spp., stool testing for, Q22 Hyperplastic polyps, 47t, Q8 Gilbert syndrome, 52 Hypertonic motility disorders, 6-7 Glasgow-Blatchford bleeding score, 77 Hypertriglyceridemia, 20 Globus sensation, 2 Hypocalcemia, pancreatitis and, 21 Glucocorticoids Hypomotility disorder, Q49 for autoimmune pancreatitis, 24 Hypotonic motility disorders, 7-8 for Crohn disease, 34t, 35 Hypovolemia, colonic ischemia and, 42 for hepatic encephalopathy, 59 Hysterectomy, prophylactic, 48 159

Index | Liver disorders, 52-71 Ibuprofen, Q59, Q91. See also NSAIDs Liver failure, 60, Q57 Idarucizumab, pre-endoscopic, 77 Liver lesions, 67-70 IgA deficiency, 29-30, Q9 Liver transplantation, 56, 70. Q57 IgA tissue transglutaminase antibodies, 29-30 LiverTox tool, 59 IgG4-related disease, 23-24 LKB1 mutations, 51 Imipenem-cilastatin, for pancreatic necrosis, 21 Loperamide, 39, Q86 Immunizations, in IBD, 36 Lower esophageal sphincter (LES), 3, 7 Immunosuppression Lower gastrointestinal bleeding (LGIB), 79-80 after liver transplantation, 70 anticoagulation during, Q64 for autoimmune hepatitis, Q18 aspirin cessation in, Q94 Infectious colitis, LGIB and, 79t causes of, 79-80, 79t Infectious esophagitis, 6 diagnostic testing in, Q23 Infiltrative liver disease, 53t management of, Q65 Inflammation, albumin levels in, 52 Lubiprostone, 37, 38t, 39 Inflammatory bowel disease (IBD), 26, 31-36 Lymphocytic colitis, 28 colonoscopy indications in, Q15 Lymphocytic gastritis, 15 colorectal cancer risk and, 46 Lynch syndrome, 24, 47-48, 49t, 50t, Q79 diagnosis of, 32-33 extraintestinal manifestations of, 31-32 M health care maintenance in, Q28 Macrocephaly, 52 LGIB and, 79t Magnesium, for constipation, 37, 38t medical treatment of, 34t Magnetic resonance cholangiopancreatography (MRCP), 20, 62 presentation, 31 Malabsorption syndromes, 30-31 primary sclerosing cholangitis and, Q15 Malignancies. See Neoplasms PSC and, 62 Malignancy risk factors, 31 ascites in, 65t small-bowel bleeding and, 81 LGIB and, 79 Inflammatory polyps, 47t small-bowel bleeding and, 81t Infliximab, 34t, 35, Q61, Q66 Mallory-Weiss tears, 75t. 78f, Q44 Insulinomas, 25 Malnutrition, 52, 67 Interferon, pegylated, for HBV infection, 55 Meckel diverticulum, 79t, 80-81, 81t Intestinal metaplasia, follow-up for, Q76 Melanomas, risks in IBD patients, 36 Intraductal papillary mucinous neoplasms, 24-25, 25f Melena, 4, 12 Intrahepatic cholestasis of pregnancy, 70 Membranoproliferative glomerulonephritis, 56 Intussusception, LGIB and, 79t 6-Mercaptopurine, 19t, 24, 34, 34t Irritable bowel syndrome (IBS), 38-39 Meropenem, for pancreatic necrosis, 21 constipation, 38-39 Mesalamine, 27t, 28, 34 diarrhea, 26-28, 38-39 Mesenteric angiography, Q63 evaluation of, 38 Mesenteric ischemia, acute (AMI), 41, 41t, Q33 management, 39 Mesenteric vein thrombosis, 41 stool testing for Giardia spp.. Q22 Metabolic liver disease, 60-61 Ischemic bowel disease, 41-42, 41t Metabolic syndrome, NAFLD and, 60-61 Metformin, diarrhea caused by, 27t, Q34 J Methotrexate, 35, 36 Jackhammer esophagus, 7 Methylcellulose, for constipation, 38t Jaundice, 23, 53, 58-59 Metoclopramide, for gastroparesis, 16 JC virus antibodies, 35 Metronidazole, 13t, 14t, 21, 35, 40, 68, Q87 Juvenile polyposis syndrome, 49t, 51f Microsatellite instability, 45 Microscopic colitis, 27-29, Q91 K Midodrine, for HRS, 66 Kayser-Fleischer rings, 61 Milan criteria, 69 Mineral supplements, diarrhea caused by, 27t L Mirtazapine, for gastroparesis, 16 Lactase deficiency, Q37 Mismatch repair genes, 47 Lactobacillus esophagitis, 6 Misoprostol, 15 Lactose malabsorption, 27, 27t, 29, 31, Q37 Mixed cryoglobulinemia, 56 Lactulose, for constipation, 38t Model for End-Stage Liver Disease (MELD) scores, 59, 63, 70 Lamivudine, 55, 70 Mucocutaneous pigmentations, 51f Laparoscopic myotomy, 7 Mucocutaneous telangiectasia, 81 Large duct obstruction, 53t Multifocal atrophic gastritis, 14 Laryngitis, GERD and, 5 Multimatrix budesonide, 34, 34t Lateral pancreaticojejunostomy, 23 Multiple endocrine neoplasia type 1, 26, Q13 Laxatives, 37, 38t Murphy sign, 72 Levofloxacin, for H. pylori infection, 13t, 14t MutYH-associated polyposis, 49t, 50 Lifestyle changes Mycobacterium avium complex (MAC), 6 for chronic pancreatitis, Q93 Mycobacterium tuberculosis, 6 for GERD, 4 Mycophenolate, for autoimmune pancreatitis, 24 for hypomotility disorder, Q49 in IBS, 39 N for nocturnal GERD, Q81 Nadolol, postendoscopy for UGIB, 78 Linaclotide, 37, 38t, 39 Narcotic bowel syndrome, 40, Q31 Lipase inhibitors, diarrhea caused by, 27t Natalizumab, for Crohn disease, 34t, 35 Lithium, diarrhea caused by, 27t Neoplasms, 79t, 80-81 Liver disease. See also Hepatic entries Nephrotic syndrome, 52, 65t abnormal chemistry in, 52, 53t Nerve blocks, for chronic pancreatitis, 23 complications of, 63-67 Neuroendocrine tumors (NETs), 17-18, 25-26 fibrosis of, 52 Neurological disorders, dysphagia and, 1 health care maintenance in, 67 Neuromuscular re-education, for constipation, 38t pregnancy-related, 70-71 Nifedipine, for achalasia, 7 severity classification, 63, 63t Nonalcoholic fatty liver disease (NAFLD), 60-61, Q35 vascular, 71 Nonalcoholic steatohepatitis, 53t

| Liver disorders, 52-71 Ibuprofen, Q59, Q91. See also NSAIDs Liver failure, 60, Q57 Idarucizumab, pre-endoscopic, 77 Liver lesions, 67-70 IgA deficiency, 29-30, Q9 Liver transplantation, 56, 70. Q57 IgA tissue transglutaminase antibodies, 29-30 LiverTox tool, 59 IgG4-related disease, 23-24 LKB1 mutations, 51 Imipenem-cilastatin, for pancreatic necrosis, 21 Loperamide, 39, Q86 Immunizations, in IBD, 36 Lower esophageal sphincter (LES), 3, 7 Immunosuppression Lower gastrointestinal bleeding (LGIB), 79-80 after liver transplantation, 70 anticoagulation during, Q64 for autoimmune hepatitis, Q18 aspirin cessation in, Q94 Infectious colitis, LGIB and, 79t causes of, 79-80, 79t Infectious esophagitis, 6 diagnostic testing in, Q23 Infiltrative liver disease, 53t management of, Q65 Inflammation, albumin levels in, 52 Lubiprostone, 37, 38t, 39 Inflammatory bowel disease (IBD), 26, 31-36 Lymphocytic colitis, 28 colonoscopy indications in, Q15 Lymphocytic gastritis, 15 colorectal cancer risk and, 46 Lynch syndrome, 24, 47-48, 49t, 50t, Q79 diagnosis of, 32-33 extraintestinal manifestations of, 31-32 M health care maintenance in, Q28 Macrocephaly, 52 LGIB and, 79t Magnesium, for constipation, 37, 38t medical treatment of, 34t Magnetic resonance cholangiopancreatography (MRCP), 20, 62 presentation, 31 Malabsorption syndromes, 30-31 primary sclerosing cholangitis and, Q15 Malignancies. See Neoplasms PSC and, 62 Malignancy risk factors, 31 ascites in, 65t small-bowel bleeding and, 81 LGIB and, 79 Inflammatory polyps, 47t small-bowel bleeding and, 81t Infliximab, 34t, 35, Q61, Q66 Mallory-Weiss tears, 75t. 78f, Q44 Insulinomas, 25 Malnutrition, 52, 67 Interferon, pegylated, for HBV infection, 55 Meckel diverticulum, 79t, 80-81, 81t Intestinal metaplasia, follow-up for, Q76 Melanomas, risks in IBD patients, 36 Intraductal papillary mucinous neoplasms, 24-25, 25f Melena, 4, 12 Intrahepatic cholestasis of pregnancy, 70 Membranoproliferative glomerulonephritis, 56 Intussusception, LGIB and, 79t 6-Mercaptopurine, 19t, 24, 34, 34t Irritable bowel syndrome (IBS), 38-39 Meropenem, for pancreatic necrosis, 21 constipation, 38-39 Mesalamine, 27t, 28, 34 diarrhea, 26-28, 38-39 Mesenteric angiography, Q63 evaluation of, 38 Mesenteric ischemia, acute (AMI), 41, 41t, Q33 management, 39 Mesenteric vein thrombosis, 41 stool testing for Giardia spp.. Q22 Metabolic liver disease, 60-61 Ischemic bowel disease, 41-42, 41t Metabolic syndrome, NAFLD and, 60-61 Metformin, diarrhea caused by, 27t, Q34 J Methotrexate, 35, 36 Jackhammer esophagus, 7 Methylcellulose, for constipation, 38t Jaundice, 23, 53, 58-59 Metoclopramide, for gastroparesis, 16 JC virus antibodies, 35 Metronidazole, 13t, 14t, 21, 35, 40, 68, Q87 Juvenile polyposis syndrome, 49t, 51f Microsatellite instability, 45 Microscopic colitis, 27-29, Q91 K Midodrine, for HRS, 66 Kayser-Fleischer rings, 61 Milan criteria, 69 Mineral supplements, diarrhea caused by, 27t L Mirtazapine, for gastroparesis, 16 Lactase deficiency, Q37 Mismatch repair genes, 47 Lactobacillus esophagitis, 6 Misoprostol, 15 Lactose malabsorption, 27, 27t, 29, 31, Q37 Mixed cryoglobulinemia, 56 Lactulose, for constipation, 38t Model for End-Stage Liver Disease (MELD) scores, 59, 63, 70 Lamivudine, 55, 70 Mucocutaneous pigmentations, 51f Laparoscopic myotomy, 7 Mucocutaneous telangiectasia, 81 Large duct obstruction, 53t Multifocal atrophic gastritis, 14 Laryngitis, GERD and, 5 Multimatrix budesonide, 34, 34t Lateral pancreaticojejunostomy, 23 Multiple endocrine neoplasia type 1, 26, Q13 Laxatives, 37, 38t Murphy sign, 72 Levofloxacin, for H. pylori infection, 13t, 14t MutYH-associated polyposis, 49t, 50 Lifestyle changes Mycobacterium avium complex (MAC), 6 for chronic pancreatitis, Q93 Mycobacterium tuberculosis, 6 for GERD, 4 Mycophenolate, for autoimmune pancreatitis, 24 for hypomotility disorder, Q49 in IBS, 39 N for nocturnal GERD, Q81 Nadolol, postendoscopy for UGIB, 78 Linaclotide, 37, 38t, 39 Narcotic bowel syndrome, 40, Q31 Lipase inhibitors, diarrhea caused by, 27t Natalizumab, for Crohn disease, 34t, 35 Lithium, diarrhea caused by, 27t Neoplasms, 79t, 80-81 Liver disease. See also Hepatic entries Nephrotic syndrome, 52, 65t abnormal chemistry in, 52, 53t Nerve blocks, for chronic pancreatitis, 23 complications of, 63-67 Neuroendocrine tumors (NETs), 17-18, 25-26 fibrosis of, 52 Neurological disorders, dysphagia and, 1 health care maintenance in, 67 Neuromuscular re-education, for constipation, 38t pregnancy-related, 70-71 Nifedipine, for achalasia, 7 severity classification, 63, 63t Nonalcoholic fatty liver disease (NAFLD), 60-61, Q35 vascular, 71 Nonalcoholic steatohepatitis, 53t 160

Index Nonceliac gluten sensitivity, 30 Polyethylene glycol, 37, 38t, 39 Non-Hodgkin lymphoma, HCV and, 56 Polymerase proofreading-associated polyposis, 49t, 50-51 Norovirus, diarrhea caused by, 26 Polypectomy, LGIB and, 80 Nortriptyline, for functional dyspepsia, Q85 Polyposis syndrome, 80-81 NSAID Porphyria cutanea tarda, 56-57, 56f PUD induced by, Q53 Portal hypertension, 52, 63-64, 66 NSAID-induced peptic ulcer disease (PUD), Q53 Portal hypertensive enteropathy, 80-81 NSAIDs Portal hypertensive gastropathy, 64, 64f, 75t adverse effects of, 67 Portal vein thrombosis, 71 colorectal cancer risk and, 46 Portopulmonary hypertension, 66-67 diarrhea caused by, 27t Postprandial distress syndrome, 10t gastrointestinal complications of, 15-16 PREdiction Model for gene Mutations 5 (PREMM.), 48 microscopic colitis and, Q91 Prednisone peptic ulcer disease and, 12 for alcoholic hepatitis, Q7 risks in IBD patients, 36 for autoimmune hepatitis, 58 small-bowel bleeding and, 81, 81t for autoimmune pancreatitis, 23-24, Q1 contraindications to, 59 0 in HBV prophylaxis, 56 Octreotide, 64, 66, 76, 81 for hepatic encephalopathy, 59 Odynophagia, 1-2 for microscopic colitis, 28 Olsalazine, for IBD, 34 during pregnancy, 70 Omeprazole, 13t, 14t, Q44, Q53, Q87 Preeclampsia, HELLP syndrome and, 70-71 Opioids Pregnancy for chronic pancreatitis, 23 antiviral therapy during, 70 constipation related to, 37 GERD during, 3 narcotic bowel syndrome and, Q31 hepatic adenomas and, 68 Oral contraceptives, hepatic adenomas and, 68 IBD management during, 36 Oropharyngeal dysphagia, 1, 2t, Q56 liver diseases related to, 70-71 Osler-Weber-Rendu syndrome, 81f Primary biliary cholangitis (PBC), 53t, 62, Q2 Osmotic diarrhea, 26-28, Q40 Primary sclerosing cholangitis (PSC), 53t, 62-63, Q15, Q27 Osteoporosis, 36, 62, 67 Probiotics, for IBS, 39 Proctitis, ulcerative colitis and, 31 P Proctosigmoiditis, 31, 33 Pain management, cirrhosis, Q82 Propranolol, postendoscopy for UGIB, 78 Palmar erythema, 59 Prostacyclin analogs, 67 Pancolitis, 33 Prostaglandin, diarrhea caused by, 27t Pancreas Protein-calorie malnutrition, 67 cystic lesions of, 24-25, 25f Prothrombin complex concentrate, 77 disorders of, 19-26 Prothrombin times, 52 ductal obstruction, 23 Proton pump inhibitors (PPIs) intraductal papillary mucinous neoplasm, 25f adverse effects of, 5t, Q44 necrosis, 21, 21f diarrhea caused by, 27t Pancreatectomy, 23 for EoE, 5-6 Pancreatic adenocarcinoma, 24 for gastrinomas, 26 Pancreatic head resection, 23 for GERD, 4-5 Pancreatic neuroendocrine tumors (PNETs), 25-26 for H. pylori infection, 13t, 14t Pancreatic pseudocysts, 21, Q32 for hypomotility disorder, Q49 Pancreaticoduodenectomy, 23 pre-endoscopic, 76 Pancreatitis, 19-23 UGIB management using, Q68 acute, 19-21, 19t, Q12, Q16, Q96 Prucalopride, for constipation, 38t autoimmune, 23-24, 23f, Ql Pseudoachalasia, 6-7 calcific, 22f Pseudocysts, pancreatic, 21 causes of, 19t Psychotherpy, for CAPS, 40 chronic, 22-23, Q93 Psyllium, 38t, 39 diagnosis of, Q12 PTEN hamartoma syndrome, 49t, 51-52 gallstone, 20 Push enteroscopy, 81, 81t phases of, 21 Pyoderma gangrenosum, 32, 32f presentation of, 19-20 Pyogenic liver abscesses, 68 small-bowel bleeding and, 81 Paracentesis, 65 Q Parkinson disease, 1 Quinolone, 76-77 Paromomycyin, 68 Parvovirus B19, 58t R Pelvic floor dyssynergia, 37 Radiation enteritis, 80-81 Peppermint oil, for IBS-D, 39 Ranson criteria, 20 Peptic ulcer disease (PUD), 12, 15, 16, 75, 75t, Q53 Rectal prolapse, 43 Percutaneous cholecystostomy tubes, 72 Rectal spasm, anal fissures and, 44 Percutaneous endovascular stenting, 42 Rectal varices, LGIB and, 79, 79t Perianal disorders, 42-44 Reflux. See Gastroesophageal reflux disease Peristalsis, swallowing and, 1 Reflux esophagitis, 3-4 Peroral endoscopic myotomy (POEM), 7 Renal dysfunction in cirrhosis, Q38 Peutz-Jeghers syndrome (PJS), 24, 49t, 51-52, 51f, 81t, Q71 Retroperitoneal fibrosis, 23 Pharyngoesophgeal (Zenker) diverticulum, 1 Rifaximin, for IBS-D, 39 Phenytoin, liver injury induced by, 59 Right colon ischemia, 41 Phosphodiesterase inhibitors, 67 Rituximab, for autoimmune pancreatitis, 24 Physical therapy for pain management, Q82 Plecanatide, 38t, 39 Ss Pleural effusions, ascites and, 65 Salmonella diarrhea, 26 Pneumatosis intestinalis, 41 Sarcoidosis, hepatic, 69 Pneumocystis jirovecii esophagitis, 6 Schatski ring, 1, 3f POLD1 mutations, 49t, 50-51 Sclerosing cholangitis, 23, 33 POLE mutations, 49t, 50-51 Sclerosing sialadenitis, 23

Nonceliac gluten sensitivity, 30 Polyethylene glycol, 37, 38t, 39 Non-Hodgkin lymphoma, HCV and, 56 Polymerase proofreading-associated polyposis, 49t, 50-51 Norovirus, diarrhea caused by, 26 Polypectomy, LGIB and, 80 Nortriptyline, for functional dyspepsia, Q85 Polyposis syndrome, 80-81 NSAID Porphyria cutanea tarda, 56-57, 56f PUD induced by, Q53 Portal hypertension, 52, 63-64, 66 NSAID-induced peptic ulcer disease (PUD), Q53 Portal hypertensive enteropathy, 80-81 NSAIDs Portal hypertensive gastropathy, 64, 64f, 75t adverse effects of, 67 Portal vein thrombosis, 71 colorectal cancer risk and, 46 Portopulmonary hypertension, 66-67 diarrhea caused by, 27t Postprandial distress syndrome, 10t gastrointestinal complications of, 15-16 PREdiction Model for gene Mutations 5 (PREMM.), 48 microscopic colitis and, Q91 Prednisone peptic ulcer disease and, 12 for alcoholic hepatitis, Q7 risks in IBD patients, 36 for autoimmune hepatitis, 58 small-bowel bleeding and, 81, 81t for autoimmune pancreatitis, 23-24, Q1 contraindications to, 59 0 in HBV prophylaxis, 56 Octreotide, 64, 66, 76, 81 for hepatic encephalopathy, 59 Odynophagia, 1-2 for microscopic colitis, 28 Olsalazine, for IBD, 34 during pregnancy, 70 Omeprazole, 13t, 14t, Q44, Q53, Q87 Preeclampsia, HELLP syndrome and, 70-71 Opioids Pregnancy for chronic pancreatitis, 23 antiviral therapy during, 70 constipation related to, 37 GERD during, 3 narcotic bowel syndrome and, Q31 hepatic adenomas and, 68 Oral contraceptives, hepatic adenomas and, 68 IBD management during, 36 Oropharyngeal dysphagia, 1, 2t, Q56 liver diseases related to, 70-71 Osler-Weber-Rendu syndrome, 81f Primary biliary cholangitis (PBC), 53t, 62, Q2 Osmotic diarrhea, 26-28, Q40 Primary sclerosing cholangitis (PSC), 53t, 62-63, Q15, Q27 Osteoporosis, 36, 62, 67 Probiotics, for IBS, 39 Proctitis, ulcerative colitis and, 31 P Proctosigmoiditis, 31, 33 Pain management, cirrhosis, Q82 Propranolol, postendoscopy for UGIB, 78 Palmar erythema, 59 Prostacyclin analogs, 67 Pancolitis, 33 Prostaglandin, diarrhea caused by, 27t Pancreas Protein-calorie malnutrition, 67 cystic lesions of, 24-25, 25f Prothrombin complex concentrate, 77 disorders of, 19-26 Prothrombin times, 52 ductal obstruction, 23 Proton pump inhibitors (PPIs) intraductal papillary mucinous neoplasm, 25f adverse effects of, 5t, Q44 necrosis, 21, 21f diarrhea caused by, 27t Pancreatectomy, 23 for EoE, 5-6 Pancreatic adenocarcinoma, 24 for gastrinomas, 26 Pancreatic head resection, 23 for GERD, 4-5 Pancreatic neuroendocrine tumors (PNETs), 25-26 for H. pylori infection, 13t, 14t Pancreatic pseudocysts, 21, Q32 for hypomotility disorder, Q49 Pancreaticoduodenectomy, 23 pre-endoscopic, 76 Pancreatitis, 19-23 UGIB management using, Q68 acute, 19-21, 19t, Q12, Q16, Q96 Prucalopride, for constipation, 38t autoimmune, 23-24, 23f, Ql Pseudoachalasia, 6-7 calcific, 22f Pseudocysts, pancreatic, 21 causes of, 19t Psychotherpy, for CAPS, 40 chronic, 22-23, Q93 Psyllium, 38t, 39 diagnosis of, Q12 PTEN hamartoma syndrome, 49t, 51-52 gallstone, 20 Push enteroscopy, 81, 81t phases of, 21 Pyoderma gangrenosum, 32, 32f presentation of, 19-20 Pyogenic liver abscesses, 68 small-bowel bleeding and, 81 Paracentesis, 65 Q Parkinson disease, 1 Quinolone, 76-77 Paromomycyin, 68 Parvovirus B19, 58t R Pelvic floor dyssynergia, 37 Radiation enteritis, 80-81 Peppermint oil, for IBS-D, 39 Ranson criteria, 20 Peptic ulcer disease (PUD), 12, 15, 16, 75, 75t, Q53 Rectal prolapse, 43 Percutaneous cholecystostomy tubes, 72 Rectal spasm, anal fissures and, 44 Percutaneous endovascular stenting, 42 Rectal varices, LGIB and, 79, 79t Perianal disorders, 42-44 Reflux. See Gastroesophageal reflux disease Peristalsis, swallowing and, 1 Reflux esophagitis, 3-4 Peroral endoscopic myotomy (POEM), 7 Renal dysfunction in cirrhosis, Q38 Peutz-Jeghers syndrome (PJS), 24, 49t, 51-52, 51f, 81t, Q71 Retroperitoneal fibrosis, 23 Pharyngoesophgeal (Zenker) diverticulum, 1 Rifaximin, for IBS-D, 39 Phenytoin, liver injury induced by, 59 Right colon ischemia, 41 Phosphodiesterase inhibitors, 67 Rituximab, for autoimmune pancreatitis, 24 Physical therapy for pain management, Q82 Plecanatide, 38t, 39 Ss Pleural effusions, ascites and, 65 Salmonella diarrhea, 26 Pneumatosis intestinalis, 41 Sarcoidosis, hepatic, 69 Pneumocystis jirovecii esophagitis, 6 Schatski ring, 1, 3f POLD1 mutations, 49t, 50-51 Sclerosing cholangitis, 23, 33 POLE mutations, 49t, 50-51 Sclerosing sialadenitis, 23 161

Index Secretagogues, for constipation, 37, 38t Transglutaminase IgA measurement, Q95 Segmental colitis with diverticulosis, 40 Transjugular intrahepatic portosystemic shunts Selective serotonin reuptake inhibitors (SSRIs), 40 (TIPS), 64, 78 Selective serotonin-norepinephrine reuptake inhibitors (SNRIs), 23, 40 Trauma, small-bowel bleeding and, 81 Senna, for constipation, 37, 38t Traveler’s diarrhea, 26, Q86 Serous cystadenoma, 25, Q69 Tricyclic antidepressants, 39, 40 Serrated polyposis syndrome, 48t, 49t, 52 Triglycerides, in pancreatitis, 20 Serrated polyps. 47t, 48t, Q8 Tuberculosis, ascites in, 65t Serum albumin levels, 52 Tubular adenoma, 47t, 48t, Q62 Serum-ascites albumin gradient, 65 Tubulovillous adenoma, 47t, 48t Shigella diarrhea, 26 Tumor necrosis factor (TNF)-«, 35 Short bowel syndrome, 30-31 “Skip lesions” in Crohn disease, 33 U SMAD4 mutations, 51 Ulcerative colitis, 31-36, 46, Q48, Q6l Small bowel obstruction, 33f Ulcerative proctitis, Q20 Small-duct primary sclerosing cholangitis (PSC), Q27 Unconjugated hyperbilirubinemia, 52 Small intestinal bacterial overgrowth (SIBO), 30, Q67 Upper gastrointestinal bleeding (UGIB) Small-bowel bleeding, 80-82, 81t, Q60 causes of, 75, 75t Small-bowel varices, 80-81 definition of, 75 Smoking, risks in IBD, 36 diagnosis of, Q52 Smoking cessation, Q93 evaluation of, 76 Sodium restriction, 65 high-risk, Q88 Somatostatin analogs, 26 management of, 76-77, 78f, Q68, Q77 Sorbital, 27, 38t Upper gastrointestinal tumors, 75t Spider angiomata, 58-59 Ursodeoxycholic acid, 62, 70 Spirulina platensis, C® labeled, 16 Ustekinumab, 34t, 35 Spontaneous bacterial peritonitis (SBP), 65, Q39 Uveitis, in IBD, 32 Squamous cell carcinoma (SCC), 9, 36, 44 Steatohepatitis, alcohol-induced, 58-59 Vv Steatorrhea, 26, 28 Vaccinations Steatosis, alcohol-induced, 58-59 HAV, 53, QI Steroid suppositories, 34t HBV, 57 STK11 mutations, 51 in patients with liver disease, 67 Stomach disorders, 10-19 risks in IBD patients, 36 Sulfasalazine, 34, 34t, 35 Valproate, 59 Swallowing, phases of, 1 Varicella zoster virus, 58t Systemic inflammatory response syndrome (SIRS), 19, 21 Vedolizumab, 34t, 35 Video capsule endoscopy, 81, 81f, Q60 T Video fluoroscopy, 1 Tacrolimus, for Crohn disease, 35 Villous adenoma, 47t, 48t Tagged red blood cell scintigraphy, 80 Viral hepatitis, 53-58, 53t, 58t. See also Hepatitis viruses Telbivudine, 55, 70 Vitamin D supplementation, 62, 67 Tenofovir, 55, 70 Vitamin K deficiency, 52 Terlipressin, for HRS, 66 Vitamin supplements, 27t Testicular atrophy, 59 Vomiting, dyspepsia and, 10 Tetracycline, for H. pylori infection, 13t, 14t, Q87 Von Hippel-Lindau syndrome, 26 Thalidomide, 81 Thiopurines, 34, 35 Ww Thiourine methyltransferase, 34 Warfarin therapy, 52, 76-77 Tinidazole, 13t, 14t, 68 Wheat dextrin, for constipation, 38t Tofacitinib, 34t, 35 Wilson disease, 53t, 61 TPMT genotype, 34 Tramadol, for chronic pancreatitis, 23 Transferrin saturation measurements, 61, Q21 Zollinger-Ellison syndrome, 18

Secretagogues, for constipation, 37, 38t Transglutaminase IgA measurement, Q95 Segmental colitis with diverticulosis, 40 Transjugular intrahepatic portosystemic shunts Selective serotonin reuptake inhibitors (SSRIs), 40 (TIPS), 64, 78 Selective serotonin-norepinephrine reuptake inhibitors (SNRIs), 23, 40 Trauma, small-bowel bleeding and, 81 Senna, for constipation, 37, 38t Traveler’s diarrhea, 26, Q86 Serous cystadenoma, 25, Q69 Tricyclic antidepressants, 39, 40 Serrated polyposis syndrome, 48t, 49t, 52 Triglycerides, in pancreatitis, 20 Serrated polyps. 47t, 48t, Q8 Tuberculosis, ascites in, 65t Serum albumin levels, 52 Tubular adenoma, 47t, 48t, Q62 Serum-ascites albumin gradient, 65 Tubulovillous adenoma, 47t, 48t Shigella diarrhea, 26 Tumor necrosis factor (TNF)-«, 35 Short bowel syndrome, 30-31 “Skip lesions” in Crohn disease, 33 U SMAD4 mutations, 51 Ulcerative colitis, 31-36, 46, Q48, Q6l Small bowel obstruction, 33f Ulcerative proctitis, Q20 Small-duct primary sclerosing cholangitis (PSC), Q27 Unconjugated hyperbilirubinemia, 52 Small intestinal bacterial overgrowth (SIBO), 30, Q67 Upper gastrointestinal bleeding (UGIB) Small-bowel bleeding, 80-82, 81t, Q60 causes of, 75, 75t Small-bowel varices, 80-81 definition of, 75 Smoking, risks in IBD, 36 diagnosis of, Q52 Smoking cessation, Q93 evaluation of, 76 Sodium restriction, 65 high-risk, Q88 Somatostatin analogs, 26 management of, 76-77, 78f, Q68, Q77 Sorbital, 27, 38t Upper gastrointestinal tumors, 75t Spider angiomata, 58-59 Ursodeoxycholic acid, 62, 70 Spirulina platensis, C® labeled, 16 Ustekinumab, 34t, 35 Spontaneous bacterial peritonitis (SBP), 65, Q39 Uveitis, in IBD, 32 Squamous cell carcinoma (SCC), 9, 36, 44 Steatohepatitis, alcohol-induced, 58-59 Vv Steatorrhea, 26, 28 Vaccinations Steatosis, alcohol-induced, 58-59 HAV, 53, QI Steroid suppositories, 34t HBV, 57 STK11 mutations, 51 in patients with liver disease, 67 Stomach disorders, 10-19 risks in IBD patients, 36 Sulfasalazine, 34, 34t, 35 Valproate, 59 Swallowing, phases of, 1 Varicella zoster virus, 58t Systemic inflammatory response syndrome (SIRS), 19, 21 Vedolizumab, 34t, 35 Video capsule endoscopy, 81, 81f, Q60 T Video fluoroscopy, 1 Tacrolimus, for Crohn disease, 35 Villous adenoma, 47t, 48t Tagged red blood cell scintigraphy, 80 Viral hepatitis, 53-58, 53t, 58t. See also Hepatitis viruses Telbivudine, 55, 70 Vitamin D supplementation, 62, 67 Tenofovir, 55, 70 Vitamin K deficiency, 52 Terlipressin, for HRS, 66 Vitamin supplements, 27t Testicular atrophy, 59 Vomiting, dyspepsia and, 10 Tetracycline, for H. pylori infection, 13t, 14t, Q87 Von Hippel-Lindau syndrome, 26 Thalidomide, 81 Thiopurines, 34, 35 Ww Thiourine methyltransferase, 34 Warfarin therapy, 52, 76-77 Tinidazole, 13t, 14t, 68 Wheat dextrin, for constipation, 38t Tofacitinib, 34t, 35 Wilson disease, 53t, 61 TPMT genotype, 34 Tramadol, for chronic pancreatitis, 23 Transferrin saturation measurements, 61, Q21 Zollinger-Ellison syndrome, 18 162